- Home
- TVGN vs NSPR Comparison
TVGN vs NSPR Comparison
Compare TVGN & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | NSPR |
|---|---|---|
| Founded | 2020 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.6M | 81.8M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TVGN | NSPR |
|---|---|---|
| Price | $0.40 | $2.03 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | ★ 1.4M | 64.4K |
| Earning Date | 11-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,779,000.00 |
| Revenue This Year | N/A | $22.76 |
| Revenue Next Year | N/A | $75.45 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.04 |
| 52 Week Low | $0.36 | $1.59 |
| 52 Week High | $1.92 | $3.80 |
Technical Indicators
Market Signals| Indicator | TVGN | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 43.20 | 53.46 |
| Support Level | $0.37 | $1.89 |
| Resistance Level | $0.40 | $2.17 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 32.47 | 72.09 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.